Noninvasive cardiac imaging
Status: Decision completed
Coronary artery disease (CAD), also referred to as coronary heart disease (CHD) or ischemic heart disease (IHD), is a leading cause of death for both men and women in the United States and is the most common form of cardiovascular disease. Accurate and early assessment of patients with symptomatic CAD is important for risk management and initiation of appropriate treatments to reduce morbidity and mortality.
For information on past related assessments, see Background.
Primary criteria ranking
- Safety = Medium
- Efficacy = Medium
- Cost = High
- Documents and related topics (2021 assessment)
- Final key questions (1/13/21)
- Noninvasive cardiac imaging for CAD: final report (10/19/21)
- Noninvasive cardiac imaging for CAD: draft findings and decision (11/5/21)
- Noninvasive cardiac imaging for CAD: final appendices (10/19/21)
- Final findings and decision (3/18/22)
- Draft key questions published: January 26, 2021
- Draft key questions public comment period: January 27 to February 11, 2021
- Final key questions published: April 22, 2021
- Draft report published: September 10, 2021
- Draft report public comment period: September 10 to October 9, 2021
- Final report published: October 20, 2021
- HTCC public meeting: November 5, 2021
The Health Technology Assessment (HTA) program conducted assessments on Coronary Computed Tomographic Angiography (CCTA) and cardiac nuclear imaging in 2008 and 2013 respectively. The current assessment will reevaluate imaging for diagnosis of CAD based on newer evidence on CCTA and stress cardiac nuclear imaging.